Coxiella burnetii is an obligate intracellular pathogen known to be the causative agent of Q fever, a zoonosis with worldwide occurrence. The organism has been found in many wild and domestic animals. Infected animals shed highly stable bacteria in urine, faeces, milk, and through placental and birth fluids. Humans acquire the infection mainly by inhaling infected aerosols, or by ingesting contaminated raw milk or fresh dairy products; tick transmission has been proven but is probably rare. The aim of the present study was to determine the titres of immunoglobulin IgG against phase I and II of C. burnetii, and to evaluate the risk factors that might be associated with exposure to C. burnetii among employees of the Veterinary University. Venous blood was obtained from 92 employees. IgG antibodies were determined by ELISA method modified in our laboratory using whole cells of the Nine Mile C. burnetii strain. The questionnaire was filled out by every subject to obtain epidemiological and clinical date. Phase I antibodies were detected in 35 subjects, i.e. in 38%, and phase II antibodies in 58 subjects, i.e. in 63%. When using the titre > or = 1:800 as a cut-off level, 2 samples were positive for phase I antibodies (2.1%) and 12 for phase II antibodies (13%). Factors predisposing to infection or exposure to C. burnetii included professional orientation and regular contact with farm animals and pets. Clinical history of some seropositive subjects revealed substantial problems, such as fever of unknown origin, rheumatic disease, disease of heart, liver, respiratory tract (particularly atypical pneumonia), chronic fatigue syndrome and spontaneous abortion in females. Q fever is a profession-related disease and prevention of its spreading within the risk population groups requires observation of basic safety rules.
Download full-text PDF |
Source |
---|
Cells
December 2024
BIH Center for Regenerative Therapies (BCRT), Therapy-Induced Remodeling in Immuno-Oncology, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
Antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells is a key mechanism in anti-cancer therapies with monoclonal antibodies, including cetuximab (EGFR-targeting) and avelumab (PDL1-targeting). Fc gamma receptor IIIa (FcγRIIIa) polymorphisms impact ADCC, yet their clinical relevance in NK cell functionality remains debated. We developed two complementary flow cytometry assays: one to predict the FcγRIIIa-V158F polymorphism using a machine learning model, and a 15-color flow cytometry panel to assess antibody-induced NK cell functionality and cancer-immune cell interactions.
View Article and Find Full Text PDFCureus
December 2024
Department of Dermatology, Asahikawa Medical University, Asahikawa, JPN.
Eczematous paradoxical reactions are commonly associated with anti-interleukin-17A (anti-IL-17A) antibodies. However, IL-23 p19 inhibitors can also cause similar cutaneous manifestations. We present a case of a 77-year-old Japanese woman with palmoplantar pustulosis (PPP), who developed eczematous lesions on her face, neck, and dorsum of the hands 10 weeks after initiating guselkumab treatment.
View Article and Find Full Text PDFTransfusion
January 2025
Blood Bank - Laboratory of Immunohematology, Centre Hospitalier Universitaire Brugmann/Université Libre de Bruxelles (ULB), Brussels, Belgium.
Background: Detection of alloantibodies associated with the JK system may be tricky. They are nevertheless associated with transfusion reactions and their detection is crucial.
Study Design And Methods: Retrospectively and over a period of 7 years, we compared the results obtained using two different assays for antibody detection.
J Transl Med
January 2025
Scientia Clinical Research and Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.
Background: A novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC) GQ1001 was assessed in patients with previously treated HER2 positive advanced solid tumors in a global multi-center phase Ia dose escalation trial.
Methods: In this phase Ia trial, a modified 3 + 3 study design was adopted during dose escalation phase. Eligible patients were enrolled, and GQ1001 monotherapy was administered intravenously every 3 weeks.
Combined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial of atezolizumab (anti-PD-L1) neoadjuvant and concurrent with CRT (Arm A) vs. concurrent with CRT (Arm B) in patients with high-risk node-positive LACC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!